{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:28:48Z","timestamp":1790339328194,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":234,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Encephalopathies are the most feared complications of sleeping sickness treatment with melarsoprol. To investigate the existence of risk factors, the incidence of encephalopathic syndromes and the relationship between the development of different types of encephalopathies and the clinical outcome was studied in a clinical trial with 588 patients under treatment with melarsoprol. The 38 encephalopathy cases were classified into three types according to the leading clinical picture: coma type, convulsion type and psychotic reactions. Nine patients were attributed to the convulsion type, defined as a transient event of short duration with convulsions followed by a post\u2010ictal phase, without signs of a generalized disease. None of these patients died from the reaction. Febrile reactions in the 48\u2003h preceding the reaction were generally not observed in this group. Twenty\u2010five patients were attributed to the coma type, which is a progredient coma lasting several days. Those patients often had signs of a generalized disease such as fever (84%), headache (72%) or bullous skin (8%) reactions. The risk of mortality was high in this group (52%). About 14\/16 patients with encephalopathic syndrome of the coma type were infected with malaria. Patients with psychotic reactions or abnormal psychiatric behaviour (3\/38) and one patient who died after alcohol intake were excluded from the analysis. The overall rate of encephalopathic syndromes in the cases analysed (<jats:italic>n<\/jats:italic>=34) was 5.8%, of which 38.2% died. We did not find any parameters of predictive value for the risk of developing an encephalopathic syndrome based on the symptoms and signs before treatment initiation. The appearance during treatment of febrile reactions (RR 11.5), headache (RR 2.5), bullous eruptions (RR 4.5) and systolic hypotension (RR 2.6) were associated with an increased risk for the occurrence of encephalopathic syndromes especially of the coma type.<\/jats:p>","DOI":"10.1046\/j.1365-3156.2001.00710.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:37:30Z","timestamp":1047505050000},"page":"390-400","source":"Crossref","is-referenced-by-count":106,"title":["Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis"],"prefix":"10.1111","volume":"6","author":[{"given":"J.","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nkunku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Burri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.1986.tb00682.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.2.298"},{"key":"e_1_2_8_4_2","first-page":"341","article-title":"2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992\u20131993","volume":"87","author":"Ancelle T","year":"1994","journal-title":"Bulletin de la Soci\u00e9t\u00e9 de Pathologie Exotique et Ses Filiales"},{"key":"e_1_2_8_5_2","first-page":"279","article-title":"\u201cL\u2019orage liquidien\u201d existe\u2010t\u2010il dasn la trypanosomiase humaine africaine trait\u00e9e par arsobal\u2010corticoides?","volume":"33","author":"Bertrand E","year":"1973","journal-title":"M\u00e9decine Tropicale (Marseille)"},{"key":"e_1_2_8_6_2","first-page":"127","article-title":"Human African trypanosomiasis, contributions of experimental models","volume":"91","author":"Bouteille B","year":"1998","journal-title":"Bulletin de la Soci\u00e9t\u00e9 de Pathologie Exotique et Ses Filiales"},{"key":"e_1_2_8_7_2","first-page":"A36","article-title":"A case of reactive encephalopathy after the treatment with suramin of first stage sleeping sickness","volume":"1","author":"Burri C","year":"1996","journal-title":"Tropical Medicine & International Health"},{"key":"e_1_2_8_8_2","first-page":"65","article-title":"Alternative application of melarsoprol for treatment of T. b. gambiense sleeping sickness. Preliminary results","volume":"75","author":"Burri C","year":"1995","journal-title":"Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02141-3"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/516130"},{"key":"e_1_2_8_11_2","first-page":"351","article-title":"Accidents observes lors du traitement de la trypanosomiase au Congo","volume":"44","author":"Ginoux PY","year":"1984","journal-title":"M\u00e9decine Tropicale (Marseille)"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1986.35.94"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91531-C"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(93)90502-H"},{"key":"e_1_2_8_15_2","unstructured":"JosenandoT(1994)Manual de Regras Para O Controlo da Tripanossom\u00edase Humana Africana. WHO for Rep\u00fablica de Angola Minist\u00e9rio de Sa\u00fade Direc\u00e7\u00e3o National de Controlo de Endemias Programa National para a Vigil\u00e2ncia e Controlo da Tripanossom\u00edase Humana Africana Luanda."},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.105990"},{"key":"e_1_2_8_17_2","first-page":"169","article-title":"A card agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T.b. gambiense trypanosomiasis","volume":"58","author":"Magnus E","year":"1978","journal-title":"Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9dicine Tropicale"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(91)90032-T"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-308X(08)60410-8"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92340-4"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(95)90673-8"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(95)90476-X"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050998"},{"key":"e_1_2_8_24_2","first-page":"39","article-title":"Advances in sleeping sickness therapy","volume":"72","author":"Van Nieuwenhove S","year":"1992","journal-title":"Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9dicine Tropicale"},{"key":"e_1_2_8_25_2","doi-asserted-by":"crossref","unstructured":"Van NieuwenhoveS(1999)Present strategies in the treatment of human African trypanosomiasis. In:Progress in Human African Trypanosomiasis Sleeping Sickness(eds M Dumas B Bouteille & A Buguet) Springer Paris pp. 253\u2013280.","DOI":"10.1007\/978-2-8178-0857-4_15"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(96)00614-6"},{"key":"e_1_2_8_27_2","first-page":"1","article-title":"Control and surveillance of African trypanosomiasis","volume":"881","author":"WHO","year":"1998","journal-title":"WHO Technical Report Series"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-3156.2001.00710.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-3156.2001.00710.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:17:19Z","timestamp":1697566639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-3156.2001.00710.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1046\/j.1365-3156.2001.00710.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-3156.2001.00710.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}